Harrow(NASDAQ) HROWL

Harrow Health, Inc. is a pharmaceutical company focused on developing, producing, and distributing innovative medications. The company operates primarily through two segments: Pharmaceutical Compounding and Pharmaceutical Drug Development, with a notable presence in the ImprimisRx business.

Products and Services

• Pharmaceutical Compounding services through ImprimisRx
• Innovative drug development for various medical conditions
• Customizable medication solutions for healthcare providers

Growth Outlook

• Revenue of $70.66 million in Q2 2026, showing potential for growth
• Trailing twelve months (TTM) gross profit margin of 73.28%
• Strong cash position with $83.89 million in cash and equivalents

Financial Highlights

• Net income of -$17.27 million in Q2 2026
• Operating income margin of -15.57% in the latest quarter
• Current ratio of 2.24, indicating strong liquidity

Harrow Health, Inc. has established itself as a key player in the pharmaceutical industry, particularly in the compounding sector. The company's focus on innovative solutions positions it well for future growth, especially as it continues to expand its product offerings. Recent financial performance indicates challenges, with a net loss reported in the latest quarter. However, the strong gross profit margin and healthy cash reserves suggest that the company has the resources to navigate these challenges and pursue growth opportunities. The current ratio reflects a solid liquidity position, which is crucial for operational stability. Overall, Harrow Health, Inc. presents an intriguing opportunity for investors interested in the pharmaceutical sector.